stockrowPTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
- Revenue
- +69.6%
- EPS
- −409.7%
- Free cash flow
- +90.3%
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
Follow PTCT
Alert me
PTC Therapeutics, Inc. (PTCT) Free cash flow
PTC Therapeutics, Inc.'s free cash flow for fiscal 2025 was $702.4M, compared with −$153.9M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$259.2M. Over the past ten years it has ranged from −$509.1M (fiscal 2022) to $702.4M (fiscal 2025) — the current reading is the highest in ten years. Free cash flow has risen for 3 consecutive fiscal years. PTC Therapeutics, Inc. ranks 561st of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $702.4M | — |
| FY2024 | −$153.9M | — |
| FY2023 | −$279.0M | — |
| FY2022 | −$509.1M | — |
| FY2021 | −$336.7M | — |
| FY2020 | −$250.0M | — |
| FY2019 | −$144.1M | — |
| FY2018 | −$43.2M | — |
| FY2017 | −$90.3M | — |
| FY2016 | −$105.3M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$31.3M | — |
| Jun 2026 | $122.0M | — |
| Mar 2026 | −$60.4M | — |
| Dec 2025 | −$36.6M | — |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$66.6M |
| MANE Veradermics Incorporated compare | −$123.0M |
| KOD Kodiak Sciences Inc. compare | −$159.9M |
| CGON CG Oncology, Inc. compare | −$179.3M |
| PTCT PTC Therapeutics, Inc. | −$259.2M |
| SRRK Scholar Rock Holding Corporation compare | −$297.0M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$308.9M |
| COGT Cogent Biosciences, Inc. compare | −$309.2M |
| IMVT Immunovant, Inc. compare | −$414.3M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on PTCT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement